Last reviewed · How we verify
Prospective Randomized Study for the Evaluation of Controlled Ovarian Stimulation With Corifollitropin Alpha in Patients With Expected or Poor Ovarian Response in IVF Cycles
Patients who have had or are expected to have a poor ovarian response (POR), because they meet any of the criteria of Bologna, can benefit from ovarian stimulation with 150 mg of alpha Corifollitropin (CFA) (Elonva ®) as single dose for a week, in the cycles of in vitro fertilization (IVF). In this study aims to demonstrate non-inferiority of the Corifollitropin Alpha (CFA ) versus daily administration of Human Menopausal Gonadotropin (hMG) (Menopur ®) during the first seven days of ovarian stimulation, in a protocol with gonadotropin-releasing hormone ( GnRH) antagonists
Details
| Lead sponsor | Instituto de Investigacion Sanitaria La Fe |
|---|---|
| Phase | Phase 3 |
| Status | COMPLETED |
| Enrolment | 234 |
| Start date | 2013-09 |
| Completion | 2017-06 |
Conditions
- Infertility
Interventions
- Ganirelix 0.25 mg.
- Recombinant choriogonadotropin alfa
- Micronized natural progesterone.
Primary outcomes
- Rate of evolutionary gestation in each cycle — 20 week of gestation
Evolutionary pregnancy has been defined as gestation of at least 1 fetus reaches 20 weeks of gestation diagnosed by normal ultrasound or confirmed by live birth - oocytes (MII) rate by patient — participants will be followed for the duration of the cycle,an expected average of 8-16 days.
When follicular puncture occurs, we value the number of punctured follicles, total oocytes and MII oocytes
Countries
Spain